Table 2.

Differences in relevant studies concerning the pegylated inteferon + ribavirin treatment of patients with hepatitis B virus/hepatitis C virus dual infection

Ref., country	Type of study	n	Severe CH or cirrhosis	HCV genotype 1b	HCV RNA SVR	Anti-HBe positive	HBV DNA detectable at baseline (n)	HBV DNA disappearance after therapy (n)	HBV DNA reappearance after therapy (n)
Senturk et al[109], Turkey	Retrospective, single center	36	13.9%	100%	5%-6%	100%	0	Not reported	Not reported
Pothoff et al[110], Germany	Prospective, multicenter, pilot study	19	10.5%	52%	93%	94.7%	6	2	4
Liu et al[111], Taiwan	Prospective, multicenter	161	40.4%	60%	72.2%-82.8%	100%	81	471	28
Viganò et al[112], Italy	Prospective, single center	223	50%	50%	41%	100%	3	22	4
Yu et al[113], China	Retrospective, single center	50	10%	60%	54%	88%	4	4	11

¹18 hepatitis B virus surface antigen (HBsAg) seroclearance;

²2 HBsAg seroclearance;

³6 cases with undetectable hepatitis B virus (HBV) DNA at baseline serocleared HBsAg after treatment. CH: Chronic hepatitis; SVR: Sustained virological response; HCV: Hepatitis C virus.